Breaking News Instant updates and real-time market news.

IDT

IDT Corp

$5.30

0.02 (0.38%)

, NIO

NIO Inc.

$7.38

1.33 (21.98%)

18:45
10/09/18
10/09
18:45
10/09/18
18:45

Fly Intel: After Hours Movers

HIGHER AFTER EARNINGS: IDT Corp (IDT) up 27.8%. ALSO HIGHER: NIO (NIO) up another 6.9% after Tesla investor disclosed 11% stake... PPG Industries (PPG) up 4.9% after Trian disclosed 2.6M stake in 13F-HR/A filing... International Paper (IP) up 2.3% after announcing $2B stock buyback and raising dividend... Avrobio (AVRO) up 1.8% after being initiated with a Buy at Guggenheim... Sangamo Therapeutics (SGMO) up 1.3% after being initiated with a Buy at Guggenheim... MongoDB (MDB) up 0.6% after acquiring mLab... Campbell Soup (CPB) up 0.5% after Third Point raised its stake. LOWER: Trinseo (TSE) down 7.7% after cutting Q3 EPS guidance due to higher raw materials... Vipshop (VIPS) down 2.6% after being downgraded to Neutral at JPMorgan... Chubb (CB) down 0.5% after filing mixed shelf.

IDT

IDT Corp

$5.30

0.02 (0.38%)

NIO

NIO Inc.

$7.38

1.33 (21.98%)

PPG

PPG

$98.57

-11 (-10.04%)

IP

International Paper

$44.63

-2.71 (-5.72%)

AVRO

Avrobio

$24.00

-1.5 (-5.88%)

SGMO

Sangamo

$14.01

-0.22 (-1.55%)

MDB

MongoDB

$68.16

-2.71 (-3.82%)

CPB

Campbell Soup

$37.53

-0.72 (-1.88%)

TSE

Trinseo

$76.15

-4.465 (-5.54%)

VIPS

Vipshop

$5.34

-0.16 (-2.91%)

CB

Chubb

$136.61

0.42 (0.31%)

  • 09

    Oct

  • 09

    Oct

  • 18

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 13

    Nov

IDT IDT Corp
$5.30

0.02 (0.38%)

03/28/18
SPIN
03/28/18
UPGRADE
SPIN
Hold
IDT Corp upgraded to Hold from Sell at Spin-Off Research
NIO NIO Inc.
$7.38

1.33 (21.98%)

10/09/18
10/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Macquarie. 2. Tellurian (TELL) initiated with a Buy at BofA/Merrill. 3. NIO Inc. (NIO) initiated with a Neutral at JPMorgan and an Overweight at Morgan Stanley. 4. Eyenovia (EYEN) initiated with a Buy at H.C. Wainwright. 5. Garrett Motion (GTX) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/18
MSCO
10/09/18
INITIATION
Target $8.5
MSCO
Overweight
NIO Inc. initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jack Yeung initiated NIO Inc. with an Overweight rating and $8.50 price target, projecting a sales volume CAGR of 54.5% in 2017-22 for China's premium EV market and contending that NIO's price advantage over foreign competitors will allow it to penetrate the market. He notes that NIO's ES8, the company's first mass-produced model, has best-in-class specifications but a lower price, partly due to local manufacturing subsidies, the absence of customs duties and reduced taxes.
10/09/18
JPMS
10/09/18
INITIATION
Target $7.5
JPMS
Neutral
NIO Inc. initiated with a Neutral at JPMorgan
JPMorgan analyst Nick Lai started NIO Inc. with a Neutral rating and $7.50 price target. The analyst wants to see a track record of execution before getting more constructive on the shares and adds that potential further capital raising could also be a risk before the company turns a profit in 2021.
10/08/18
10/08/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. BARCLAYS BOOSTS GE TO OVERWEIGHT: Barclays analyst Julian Mitchell upgraded General Electric (GE) to Overweight from Equal Weight with an unchanged price target of $16. The analyst said that while he does not yet know the magnitude of the 2018 guidance cuts, his talks with investors suggest they are braced for earnings per share of 75c for 2018, free cash flow of 50c, and a dividend cut of 75%-plus. PIPER JAFFRAY CUTS IROBOT TO NEUTRAL: Piper Jaffray analyst Troy Jensen downgraded iRobot (IRBT) to Neutral with an unchanged price target of $90. The analyst continues to believe the robotic vacuum market is in a secular uptrend and that iRobot will "maintain its dominant position in the market." However, Jensen has become "incrementally more concerned" with the stock's valuation following the year-to-date outperformance. NIO INITIATED BY MULTIPLE FIRMS: Deutsche Bank analyst Vincent Ha started NIO Inc. (NIO) with a Buy rating and $9.50 price target. The company's electric vehicles in China are "prepared to challenge the status quo," Ha said. Additionally, Wolfe Research initiated NIO with an Outperform and $8 price target, and Goldman Sachs started NIO Inc. with a Neutral rating and $6.56 price target. GOLDMAN BOOSTS SQUARE PRICE TARGET: Goldman Sachs analyst James Schneider increased his price target on Square (SQ) to $108 from $77 after raising his 2018-20 revenue estimates given he now sees more upside than in his prior estimates across a range of Square's business lines. He also raised his multiple on the stock, saying that Square is one of the only companies sustaining over 50% revenue growth while simultaneously delivering substantial margin expansion. Schneider, who model about 2.5X faster growth than PayPal (PYPL) and about 5X faster growth than merchant acquirers for Square through 2020, reiterated Buy rating on Square shares. CITI BOOSTS APPLE PRICE TARGET: Citi analyst Jim Suva raised his price target for Apple (AAPL) to $265 and reiterated a Buy rating on the shares. Suva increased his financial model for Apple to reflect higher average selling prices and stronger gross margins given the consumer preference for higher memory configurations of iPhones coupled with falling memory prices.
PPG PPG
$98.57

-11 (-10.04%)

10/09/18
VERT
10/09/18
DOWNGRADE
VERT
Hold
PPG downgraded to Hold from Buy at Vertical Research
07/27/18
JPMS
07/27/18
DOWNGRADE
Target $110
JPMS
Neutral
PPG downgraded to Neutral on valuation at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded PPG Industries (PPG) to Neutral from Overweight with an unchanged price target of $110. The analyst cites valuation for the downgrade as he sees a "relatively low level of capital appreciation to be captured from the current share price." Axalta Coating (AXTA) shares are a good value among the coatings companies at this juncture, Zekauskas tells investors in a research note. The analyst upgraded Axalta this morning to Overweight.
09/24/18
FBCO
09/24/18
DOWNGRADE
FBCO
Neutral
PPG downgraded to Neutral from Outperform at Credit Suisse
09/24/18
09/24/18
DOWNGRADE
Target $119

Neutral
PPG downgraded to Neutral on limited upside at Credit Suisse
As previously reported, Credit Suisse analyst Christopher Parkinson downgraded PPG to Neutral from Outperform, with a $119 price target. The analyst believes the 15%-plus rally in the shares since the June low of about $100/share is justified, but it has run its relative course. While Parkinson sees a path to earnings growth in 2019 on better price/cost balance, a large buyback program, solid growth in Performance, and further progress on cost-cutting efforts, he believes the vast majority of these tailwinds are now priced-in.
IP International Paper
$44.63

-2.71 (-5.72%)

10/09/18
BMOC
10/09/18
DOWNGRADE
BMOC
Market Perform
International Paper downgraded to Market Perform from Outperform at BMO Capital
10/09/18
BMOC
10/09/18
DOWNGRADE
Target $51
BMOC
Market Perform
International Paper cut to Market Perform at BMO Capital on supply capacity
As reported earlier, BMO Capital analyst Mark Wilde downgraded International Paper to Market Perform from Outperform and lowered his price target to $51 from $66. The analyst points to the "growing list of containerboard supply additions" - the biggest capacity surge in over two decades - even though the valuation on the stock doesn't look expensive. Wilde adds that it remains unclear over how the incremental capacity will be absorbed, with demand growth already slowing in spite of the "robust" macro economy, and lowers his FY19 EBITDA view to $4.3B from $4.4B.
09/11/18
SPHN
09/11/18
NO CHANGE
SPHN
Equal Weight
International Paper exec changes a chance to shift narrative, says Stephens
Stephens analyst Mark Connelly said he does not expect the retirement of C. Cato Ealy, the "architect of IP's M&A strategy for nearly three decades," to result in a substantial shift in direction, but he does believe that his departure and the "unexpected exit" previously of CFO Glenn Landau give International Paper CEO Mark Sutton another opportunity to shift the narrative and possibly strategy as well. Connelly keeps an Equal Weight rating and $57 price target on International Paper shares.
07/23/18
07/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Spotify (SPOT) initiated with a Buy at BTIG. 2. BJ's Wholesale (BJ) initiated with an Outperform at William Blair and Baird, a Buy at Jefferies, BofA/Merrill, Citi, and Nomura Instinet, an Equal Weight at Morgan Stanley, a Market Perform at Wells Fargo, as well as a Neutral at JPMorgan, and Goldman Sachs. 3. EverQuote (EVER) initiated with an Overweight at JPMorgan, an Outperform at JMP Securities, Oppenheimer, and William Blair, a Buy at Canaccord and BofA/Merrill, as well as a Market Perform at Raymond James. 4. International Paper (IP) resumed with a Buy at Citi. 5. Centene (CNC) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AVRO Avrobio
$24.00

-1.5 (-5.88%)

10/09/18
GUGG
10/09/18
INITIATION
GUGG
Buy
Avrobio initiated with a Buy at Guggenheim
Guggenheim analyst Whitney Ijem initiated Avrobio with a Buy rating and $35 price target, calling the two-day 61% sell off on the company's Ph1 Fabry data update an overreaction.
09/17/18
HCWC
09/17/18
INITIATION
Target $47
HCWC
Buy
Avrobio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Avrobio with a Buy rating and $47 price target. The status quo in the treatment of lysosomal storage disorders is likely to be disrupted, Chattopadhyay tells investors in a research note. The analyst recommends being opportunistic on pullbacks and building a position in the name.
07/16/18
COWN
07/16/18
INITIATION
COWN
Outperform
AvroBio initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated AvroBio with an Outperform rating citing its four programs that have been generated from its lentiviral gene therapy platform for lysomal storage diseases. The analyst expects the company to create long-term value with its gene therapy programs.
07/16/18
WELS
07/16/18
INITIATION
Target $40
WELS
Outperform
AvroBio initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started AvroBio with an Outperform rating and $40 price target based on what he views as a differentiated capability in applying lentiviral-based gene therapy, a proven platform with curative potential, to lysosomal storage diseases, proof-of-mechanism afforded by existing LSD treatment approaches including enzyme replacement therapy and allogeneic hematopoietic stem cell transplant, encouraging initial phase 1 data in Fabry disease demonstrating rapid, robust, and sustained enzyme expression, and a leverageable platform that extends to multiple LSDs with established markets and multibillion dollar opportunities.
SGMO Sangamo
$14.01

-0.22 (-1.55%)

10/09/18
GUGG
10/09/18
INITIATION
GUGG
Buy
Sangamo initiated with a Buy at Guggenheim
Guggenheim analyst Whitney Ijem initiated Sangamo with a Buy rating and $18 price target, citing the company's diversified tech platform, pipeline, progress on partnerships, and the new TxCell acquisition.
09/06/18
JEFF
09/06/18
NO CHANGE
Target $28
JEFF
Buy
Sangamo selloff yesterday an overreaction, says Jefferies
Jefferies analyst Maury Raycroft views the selloff yesterday in shares of Sangamo Therapeutics as an overreaction. Though Street expectations "were misaligned" heading into the initial genome-editing Mucopolysaccharidosis Type II data reported yesterday, initial results demonstrated success and set the stage for additional validating data, Raycroft tells investors in a research note. He believes Sangamo's platform is "robust/valuable" and points out that the company's expects up to five pivotal programs in next few years. The analyst keeps a Buy rating on the shares with a $28 price target.
08/09/18
JEFF
08/09/18
NO CHANGE
Target $28
JEFF
Buy
Jefferies sees 'excellent entry point' for Sangamo after data
Jefferies analyst Maury Raycroft believes current share levels offer an "excellent entry point" into Sangamo Therapeutics following the company's hemophilia A data. While early, the data is "looking good," Raycroft tells investors in a research note. He believes Sangamo is aiming for best-in-class versus first-to-market. Two clinical catalysts for Sangamo have now been substantially de-risked, Raycroft contends. He recommends buying the stock and keeps a $28 price target for the shares.
06/20/18
BOFA
06/20/18
INITIATION
Target $24
BOFA
Buy
Sangamo initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Qian Wang initiated Sangamo with a Buy and $24 price target saying it has one of the most advanced pipelines in the clinic using zinc finger protein technology. Wang said Sangamo has established partnerships with major players that validates the technology and expects multiple catalysts throughout 2H 2018 and beyond.
MDB MongoDB
$68.16

-2.71 (-3.82%)

09/17/18
LEHM
09/17/18
NO CHANGE
Target $105
LEHM
Overweight
MongoDB price target raised to $105 from $79 at Barclays
Barclays analyst Raimo Lenschow raised his price target for MongoDB to $105 after basing his valuation on a long-term model. MongoDB looks well positioned as the leading vendor in the NoSQL market, which is estimated to grow at more than 30% annually through 2023, Lenschow tells investors in a research note. The analyst keeps an Overweight rating on the shares.
10/02/18
DADA
10/02/18
INITIATION
Target $80
DADA
Neutral
MongoDB initiated with a Neutral at DA Davidson
DA Davidson analyst Rishi Jaluria initiated MongoDB with a Neutral rating and a price target of $80. The analyst notes that he is positive on the company's "strong value proposition, rapid growth, and unique model". However, Jaluria also sees MongoDB valuation as "fair" at 15-times enterprise value to expected FY19 revenues and after a 166% year-to-date run-up would rather wait for a pullback to get more constructive on the name.
10/02/18
NOMU
10/02/18
DOWNGRADE
Target $63
NOMU
Reduce
Nomura downgrades MongoDB to Reduce on 'extreme valuation'
Nomura Instinet Christopher Eberle downgraded MongoDB (MDB) to Reduce from Neutral while raising his price target for the shares to $63 from $43. The stock closed yesterday at $78.86. The company's current market value reflects "extreme valuation," Eberle tells investors in a research note. MongoDB has a "compelling" multi-year, if not multi-decade, opportunity, but it faces "intense competition and deep-pocketed incumbency that won't die easily," the analyst contends. He points out that in the last year alone, Microsoft's (MSFT) Cosmos DB grew from zero to $100M revenue. Eberle believes the current market price of MongoDB assumes no risks.
10/02/18
NOMU
10/02/18
DOWNGRADE
NOMU
Reduce
MongoDB downgraded to Reduce from Neutral at Nomura Instinet
CPB Campbell Soup
$37.53

-0.72 (-1.88%)

09/05/18
WOLF
09/05/18
DOWNGRADE
WOLF
Underperform
Campbell Soup downgraded to Underperform from Peer Perform at Wolfe Research
08/31/18
DBAB
08/31/18
NO CHANGE
Target $36
DBAB
Hold
Campbell Soup price target lowered to $36 from $40 at Deutsche Bank
Deutsche Bank analyst Rob Dickerson lowered his price target for Campbell Soup to $36 saying that while the company topped earnings expectations in Q4, its top line remained pressured, leaving investment needs high. Along with the lack of growth in the Global Biscuits and Snacks division, Americas Simple Meals and Beverages posted a 6% organic sales decline, with soup down 14% and issues at Walmart ongoing, Dickerson tells investors in a post-earnings research note titled "The Eight-Year Giveback." He keeps a Hold rating on Campbell Soup.
08/31/18
JPMS
08/31/18
NO CHANGE
Target $36
JPMS
Underweight
Campbell's remaining operations face significant challenges, says JPMorgan
JPMorgan analyst Ken Goldman generally agrees with Campbell Soup management that a more focused portfolio will enable better execution and that many cost savings opportunities have yet to be realized. However, But Campbell's remaining operations still face significant challenges, some of which are likely to intensify in the coming year, Goldman tells investors in a research note. He reiterates an Underweight rating on the shares with a year-end 2019 price target of $36.
08/31/18
FBCO
08/31/18
NO CHANGE
Target $36
FBCO
Underperform
Campbell Soup portfolio simplified, but not enough, says Credit Suisse
After Campbell Soup announced it will divest 20% of its portfolio to de-leverage and refocus on its core businesses in North America, Credit Suisse analyst Robert Moskow said the portfolio simplification plans are not enough. He finds it difficult to embrace the company's new long-term guidance for 7-9% EPS growth and sees "considerable downside risk" to its debt reduction target, Moskow tells investors. He raised his price target on Campbell shares to $36 from $32 to account for a more logical path forward and higher sector multiples, but he keeps an Underperform rating on the stock.
TSE Trinseo
$76.15

-4.465 (-5.54%)

01/30/18
JEFF
01/30/18
NO CHANGE
Target $97
JEFF
Buy
Trinseo price target raised to $97 from $85 at Jefferies
Jefferies analyst Laurence Alexander raised his price target for Trinseo to $97 saying a higher level of turnarounds in the first half of 2018 compared to last year and "healthy" demand levels suggest upside to 2018 earnings from outages. The analyst keeps a Buy rating on the shares.
01/17/18
WELS
01/17/18
NO CHANGE
Target $84
WELS
Outperform
Trinseo price target raised to $84 from $79 at Wells Fargo
Wells Fargo analyst Frank Mitsch raised his price target for Trinseo to $84 from $79 on tax reform. The analyst reiterates an Outperform rating on the shares.
02/21/18
DBAB
02/21/18
NO CHANGE
Target $96
DBAB
Buy
Trinseo valuation 'compelling' after Q4 results, says Deutsche Bank
Deutsche Bank analyst David Begleiter views Trinseo's valuation as "compelling" following the company's inline Q4 results and 2018 EBITDA guidance raise. The company's positive outlook is supported by tight styrene supply/demand balances, Begleiter tells investors in a research note. He keeps a Buy rating on the shares with a $96 price target.
04/03/18
DBAB
04/03/18
NO CHANGE
Target $96
DBAB
Buy
Trinseo recent stock weakness overdone, says Deutsche Bank
Deutsche Bank analyst David Begleiter views the 11% pullback over the past three weeks in shares of Trinseo as overdone. Trinseo is once again one of the cheapest stocks in chemicals, Begleiter tells investors in a research note. While concerns over new styrene capacity are justified as a significant portion of Trinseo's shares quadrupling over the past three years was due to strong styrene margins, the size of the discount being applied to Trinseo shares is "too severe," Begleiter writes. He keeps a Buy rating on the name with a $96 price target.
VIPS Vipshop
$5.34

-0.16 (-2.91%)

10/09/18
JPMS
10/09/18
DOWNGRADE
JPMS
Neutral
Vipshop downgraded to Neutral from Overweight at JPMorgan
08/15/18
BNCH
08/15/18
NO CHANGE
Target $12
BNCH
Buy
Vipshop price target lowered to $12 from $19 at Benchmark
Benchmark analyst Fawne Jiang lowered her price target on Vipshop (VIPS) to $12 after the company reported soft Q2 results and gave Q3 guidance that indicated an organic revenue deceleration on top of a limited contribution from the Tencent (TCEHY) and JD.com (JD) channels. She believes Vipshop continues to face growth challenges due to increasing competition and changing industry dynamics in China, but keeps a Buy rating on the shares as she expects significant synergies to be unlocked from the Tencent and JD partnerships over the longer-term.
08/14/18
SBSH
08/14/18
DOWNGRADE
SBSH
Sell
Vipshop downgraded to Sell from Buy at Citi
Citi analyst Alicia Yap downgraded Vipshop to Sell from Buy and cut its price target to $8 from $17 citing declining margins and decelerating growth.
08/14/18
LYON
08/14/18
DOWNGRADE
LYON
Underperform
Vipshop downgraded to Underperform from Outperform at CLSA
CLSA analyst Man Ho Lam downgraded Vipshop to Underperform from Outperform with an $8.50 price target citing the disappointing Q2 report and weak Q3 guidance.
CB Chubb
$136.61

0.42 (0.31%)

08/14/18
08/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chubb (CB) downgraded to Sell from Hold at Deutsche Bank with analyst Joshua Shanker saying the company's recent quarterly results show that Chubb, post-merger, is unable to grow its business at the levels of its peers. 2. Switch (SWCH) was downgraded to Market Perform from Outperform at Raymond James, to Neutral from Overweight at JPMorgan, and to Neutral from Buy at BTIG. 3. Urban Outfitters (URBN) downgraded to Neutral from Outperform at Baird with analyst Mark Altschwager citing valuation. 4. Premier (PINC) downgraded to Hold from Buy at Canaccord with analyst Richard Close citing its quarter-to-date outperformance. 5. Parker-Hannifin (PH) downgraded to Hold from Buy at Argus with analyst John Eade saying that while the company's recent Q4 results topped expectations, management's outlook for FY19 was worse than expected. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/18
DBAB
08/13/18
DOWNGRADE
Target $126
DBAB
Sell
Deutsche Bank downgrades Chubb to Sell with $126 price target
Deutsche Bank analyst Joshua Shanker downgraded Chubb to Sell and lowered his price target for the shares to $126 from $135. The company's recent quarterly results show that Chubb, post-merger, is unable to grow its business at the levels of its peers, Shanker tells investors in a research note. Further, the analyst believes the company is unlikely to maintain its current underwriting margins and that consensus estimates will need to be revised downward.
08/13/18
DBAB
08/13/18
DOWNGRADE
Target $126
DBAB
Sell
Chubb downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Joshua Shanker downgraded Chubb to Sell and lowered his price target for the shares to $126 from $135. The stock closed the trading day down 92c to $134.98.
08/07/18
FBCO
08/07/18
INITIATION
Target $141
FBCO
Neutral
Travelers initiated with a Neutral at Credit Suisse
Credit Suisse analyst Michael Zaremski started Travelers (TRV) with a Neutral rating and $141 price target. For shorter-term oriented investors, the analyst recommends Travelers over peer Chubb (CB) due to having more conviction over its recent string of higher than expected non-catastrophe weather-related losses subsiding, a greater gearing to workers' comp. leading to a steady stream of reserve releases given an extremely healthy unemployment backdrop, and conviction that near-term auto margins will continue to improve given industry pricing dynamics. In the longer term, he struggles to make the case that Travelers' wheels business can produce better and less volatile results.

TODAY'S FREE FLY STORIES

JEC

Jacobs Engineering

$74.22

0.45 (0.61%)

11:48
02/22/19
02/22
11:48
02/22/19
11:48
Conference/Events
Jacobs Engineering management to meet with KeyBanc »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 12

    Mar

TCDA

Tricida

$23.11

0.84 (3.77%)

11:46
02/22/19
02/22
11:46
02/22/19
11:46
Initiation
Tricida initiated  »

Tricida initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$109.87

-1.89 (-1.69%)

11:45
02/22/19
02/22
11:45
02/22/19
11:45
Options
UPS call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

11:45
02/22/19
02/22
11:45
02/22/19
11:45
General news
More from Williams: the Phillips Curve needs to be taken seriously »

More from Williams: the…

OCUL

Ocular Therapeutix

$4.22

0.61 (16.90%)

11:37
02/22/19
02/22
11:37
02/22/19
11:37
Hot Stocks
Ocular Therapeutix higher after pricing $37.5M in convertible notes »

Shares of Ocular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
02/22/19
02/22
11:35
02/22/19
11:35
General news
The Fed's Monetary Policy Report »

The Fed's Monetary…

AXNX

Axonics

$21.65

-0.85 (-3.78%)

11:33
02/22/19
02/22
11:33
02/22/19
11:33
Hot Stocks
Axonics granted expanded CE mark label approval for Axonics r-SNM System »

Axonics Modulation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 05

    Mar

EA

Electronic Arts

$95.01

-1.825 (-1.88%)

11:30
02/22/19
02/22
11:30
02/22/19
11:30
Options
Buyer pays $3.3M for EA upside calls as shares drop 2% »

Buyer pays $3.3M for EA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

VLKAY

Volkswagen

$0.00

(0.00%)

11:27
02/22/19
02/22
11:27
02/22/19
11:27
Periodicals
VW CEO says he hopes company did enough 'to avoid import taxes', CNBC reports »

Volkswagen CEO Herbert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$19.10

1.68 (9.64%)

11:25
02/22/19
02/22
11:25
02/22/19
11:25
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

MDT

Medtronic

$93.25

0.65 (0.70%)

11:25
02/22/19
02/22
11:25
02/22/19
11:25
Conference/Events
Medtronic participates in a conference call with JPMorgan »

Healthcare Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
02/22/19
02/22
11:17
02/22/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
02/22/19
02/22
11:16
02/22/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/22/19
02/22
11:15
02/22/19
11:15
General news
Fed's Daly said the Fed should aim to hit the 2% inflation target on average »

Fed's Daly said the…

TOT

Total

$56.80

0.74 (1.32%)

11:11
02/22/19
02/22
11:11
02/22/19
11:11
Periodicals
Total cancels sale of Dutch North Sea gas fields, Bloomberg reports »

Total has called off a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 04

    Mar

  • 22

    May

CZR

Caesars

$9.01

-0.41 (-4.35%)

11:10
02/22/19
02/22
11:10
02/22/19
11:10
Options
Post-earnings put roll in Caesars adjusts yesterday's big spread »

Post-earnings put roll in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$294.87

3.69 (1.27%)

, MS

Morgan Stanley

$41.91

-0.05 (-0.12%)

11:07
02/22/19
02/22
11:07
02/22/19
11:07
Periodicals
Tesla CEO looks to Morgan Stanley for five major mortgages, Bloomberg reports »

Tesla (TSLA) CEO Elon…

TSLA

Tesla

$294.87

3.69 (1.27%)

MS

Morgan Stanley

$41.91

-0.05 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 04

    Mar

  • 18

    Mar

  • 19

    Mar

BDRBF

Bombardier

$0.00

(0.00%)

11:05
02/22/19
02/22
11:05
02/22/19
11:05
Hot Stocks
Bombardier to invest $22M in two aerospace research projects in Quebec »

Bombardier announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZG

Zillow

$40.94

5.87 (16.74%)

, Z

Zillow

$41.12

6.09 (17.39%)

11:03
02/22/19
02/22
11:03
02/22/19
11:03
Hot Stocks
Zillow adds to gain as Citron sets $70 target, turns positive after CEO change »

Shares of Zillow Group…

ZG

Zillow

$40.94

5.87 (16.74%)

Z

Zillow

$41.12

6.09 (17.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

BECN

Beacon Roofing

$37.50

0.13 (0.35%)

11:02
02/22/19
02/22
11:02
02/22/19
11:02
Hot Stocks
Beacon Roofing announces departure of CEO Paul Isabella later this year »

Beacon Roofing Supply…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

C

Citi

$64.03

-0.28 (-0.44%)

11:00
02/22/19
02/22
11:00
02/22/19
11:00
Options
Active trading in Citigroup short-term puts »

Active trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Apr

  • 28

    May

  • 13

    Jul

ZG

Zillow

$40.54

5.47 (15.60%)

, Z

Zillow

$40.94

5.91 (16.87%)

10:57
02/22/19
02/22
10:57
02/22/19
10:57
Periodicals
Citron says now positive on Zillow, calls returning CEO a 'stud' »

Citron Research tweeted:…

ZG

Zillow

$40.54

5.47 (15.60%)

Z

Zillow

$40.94

5.91 (16.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

ZG

Zillow

$40.54

5.47 (15.60%)

, Z

Zillow

$40.94

5.91 (16.87%)

10:57
02/22/19
02/22
10:57
02/22/19
10:57
Periodicals
Breaking Periodicals news story on Zillow, Zillow »

Citron Research turns…

ZG

Zillow

$40.54

5.47 (15.60%)

Z

Zillow

$40.94

5.91 (16.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 25

    Mar

PFE

Pfizer

$43.02

0.88 (2.09%)

10:55
02/22/19
02/22
10:55
02/22/19
10:55
Periodicals
Pfizer exec to host presidential fundraiser for Gillibrand campaign, CNBC says »

Pfizer's executive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 18

    May

PLNT

Planet Fitness

$59.40

1.14 (1.96%)

10:50
02/22/19
02/22
10:50
02/22/19
10:50
Options
Earnings hedge opened in Planet Fitness »

Earnings hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.